HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Advances in chronic lymphocytic leukemia suggest progress is ‘visible on the horizon’
-
- Is ibrutinib-based therapy the preferred initial treatment for all patients with CLL?
- The potential benefits (and pitfalls) of real-world evidence in oncology John Sweetenham, MD, FRCP, FACP
- Immunotherapy for head and neck cancer an evolving paradigm Charu Aggarwal, MD, MPH
- Treatment response in AML: Understanding available molecular diagnostic data Megan Wheelden, MD; David F. Claxton, MD
- Penile squamous cell carcinoma may benefit from therapies used in HPV-related cancers
- Researchers identify genomic drivers of poor survival, enzalutamide resistance in advanced prostate cancer
- Colorectal cancer in young patients often misdiagnosed, identified at late stage
- Lung cancer ‘personifies precision medicine’
-
- Genetic testing can detect melanoma earlier, but tailored approach is required
- Alpelisib prolongs PFS in breast cancer subset
- Preoperative breast MRI valuable complement to mammography, ultrasound
- Daratumumab regimen yields durable responses in relapsed, refractory multiple myeloma
- Hydroxyurea benefits children from sub-Sahara Africa with sickle cell anemia
- Pembrolizumab granted priority review for three oncology indications
- FDA expands Sprycel approval to include certain children with acute lymphoblastic leukemia
- FDA expands Alimta approval for lung cancer
-
- FDA approves subcutaneous Herceptin Hylecta for HER2-positive breast cancer